- Middle Antibody drug conjugates (ADCs), which combine the targeting ability of monoclonal antibodies with the cytotoxic potency of chemotherapy agents, are gaining traction as a transformative cancer treatment across the Middle East and Africa due to their precision, reduced side effects, and improved clinical outcomes in oncology care
- The growing demand for ADCs is primarily fueled by rising cancer prevalence, increasing focus on personalized medicine, and expanding access to advanced therapeutic options through government and private sector investments
- South Africa dominated the Middle East and Africa antibody drug conjugates (ADC) market in with the largest revenue share of 28.9% in 2024, supported by its advanced healthcare infrastructure, strong oncology research base, and early adoption of biologic therapies through clinical collaborations and public-private partnerships
- Saudi Arabia is expected to be the fastest-growing country in the Middle East and Africa antibody drug conjugates (ADC) market during the forecast period due to accelerated healthcare modernization, rising oncology diagnosis rates, and initiatives to localize pharmaceutical manufacturing and strengthen regulatory approvals for biologics
- The breast cancer segment dominated the Middle East and Africa antibody drug conjugates (ADC) market in the Middle East and Africa with a market share of 40.2% in 2024, driven by its high incidence and increasing deployment of targeted ADC therapies for HER2-positive and triple-negative breast cancer cases across both public and private oncology centers
